Bayer on the right track for an effective 2012 The Bayer Group remains on a path of growth.

We stick to a successful route, and we confirm our assistance for 2012. EBIT before special products elevated by 1.7 % to EUR 1,194 million . Revenue before curiosity, taxes, depreciation and amortization – before special products – were up by 2.2 % to EUR 1,845 million . Net gain fell by 17.8 % to EUR 528 million . Core income per talk about advanced by 7.1 % to EUR 1.20 . Gross cashflow declined by 22.9 % to EUR 1,023 million , due to the fact of the low EBIT. Net cashflow, however, rose by 26.1 % to EUR 1,989 million because of a seasonal reduction in cash tangled up in working capital. Net credit card debt was decreased from EUR 7.on June 30 9 billion, 2012, to EUR 6.on September 30 8 billion, 2012 because of the operating cashflow.BPA has frequently been implicated in disease or developmental problems. Long recognized to become an artificial estrogen, the principal hormone involved with female sexual development, BPA has been proven to improve breast cancer cell development already, in the January 2005 edition of the journal Cancer tumor Research and, another UC research group reported that it elevated the development of some prostate tumor cells as well. Warnings about other feasible long-term health risks connected with fetal exposures to BPA are also discussed in latest scientific literature.